Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial
HOTH Stock | USD 0.85 0.01 1.16% |
Under 61% of Hoth Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading Hoth Therapeutics stock suggests that many investors are alarmed at this time. Hoth Therapeutics' investing sentiment shows overall attitude of investors towards Hoth Therapeutics.
Hoth |
Hoth Therapeutics, Inc. , a patient-focused biopharmaceutical company, today announced today that it has received Institutional Review Board approval from the Montefiore Medical Center and the Dana-Farber Cancer Institute to proceed with its First-in-Human Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors .
Read at finance.yahoo.com
Hoth Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Hoth Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Hoth Therapeutics Fundamental Analysis
We analyze Hoth Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hoth Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hoth Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
Hoth Therapeutics is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Hoth Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Hoth Therapeutics stock to make a market-neutral strategy. Peer analysis of Hoth Therapeutics could also be used in its relative valuation, which is a method of valuing Hoth Therapeutics by comparing valuation metrics with similar companies.
Peers
Hoth Therapeutics Related Equities
CDIO | Cardio Diagnostics | 40.74 | ||||
ATNF | 180 Life | 3.83 | ||||
ADTX | Aditxt | 1.11 | ||||
ALLR | Allarity Therapeutics | 1.90 | ||||
ATXI | Avenue Therapeutics | 2.11 | ||||
VRAX | Virax Biolabs | 2.35 | ||||
NRBO | Neurobo Pharmaceuticals | 2.59 | ||||
KPRX | Kiora Pharmaceuticals | 3.57 | ||||
PHIO | Phio Pharmaceuticals | 3.91 | ||||
BDRX | Biodexa Pharmaceticals | 4.91 | ||||
SONN | Sonnet Biotherapeutics | 5.24 | ||||
QNRX | Quoin Pharmaceuticals | 6.05 | ||||
REVB | Revelation Biosciences | 6.67 | ||||
ZURA | Zura Bio | 20.86 |
Complementary Tools for Hoth Stock analysis
When running Hoth Therapeutics' price analysis, check to measure Hoth Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hoth Therapeutics is operating at the current time. Most of Hoth Therapeutics' value examination focuses on studying past and present price action to predict the probability of Hoth Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hoth Therapeutics' price. Additionally, you may evaluate how the addition of Hoth Therapeutics to your portfolios can decrease your overall portfolio volatility.
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume |